Esperion Falls Victim To Amgen's Poor Repatha Results

Esperion Therapeutics Inc ESPR shares are trading lower by $5.10 (18 percent) at $24.55 in Friday's session. It's being dragged down by poor results from cholesterol drug testing that's having a major negative impact on related stocks in the sector.

The primary catalyst for the biotech bashing is Amgen Inc. AMGN. Shares are trading lower by $12.00 at $168.11, when results for Repatha didn't meet Wall Street expectations.

In another sympathy move, Regeneron Pharmaceuticals REGN shares are trading lower by $19.50 at $373.09.

While Amgen (lower by roughly 6 percent) and Regeneron (lower by over 4 percent) are struggling to recover, Esperion was hit hardest and has been attempting to rebound.

After a lower open, Esperion's stock bottomed in the first seven minutes of the session at $20.39 and has climbed into the $23.00 handle. That low coincides with its February 15 low ($20.47). Since reaching that depressed level, it has continued to make new highs for the session, with the current one standing at $24.53.